<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02933931</url>
  </required_header>
  <id_info>
    <org_study_id>2016-00918</org_study_id>
    <nct_id>NCT02933931</nct_id>
  </id_info>
  <brief_title>Immune Durability After VSV-EBOV Vaccination</brief_title>
  <official_title>Long-term Immune Durability After Vaccination With the Vesicular Stomatitis Virus-vectored Zaire Ebola Candidate Vaccine (VSV-EBOV): a Prospective Observational Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective observational cohort study will follow the roughly 100 adults who received
      the VSV-ZEBOV vaccine in the Geneva phase 1 randomized controlled trial in 2014-2015 in order
      to determine their long-term (5-year) immune response to vaccination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: During the Ebola epidemic of 2014-5, there was no proven therapy or prevention
      available beyond horizontal infection control measures. After the Canadian government donated
      800 vials of the vaccine candidate VSV-EBOV to World Health Organization (WHO), the
      University Hospitals of Geneva agreed to perform a WHO-coordinated phase I/II double-blind,
      placebo-controlled randomized trial to assess the candidate's safety and immunogenicity
      healthy adult volunteers. The doses of 10 E7 pfu and 5 x 10 E7 pfu were tested in 35 and 16
      volunteers, respectively, before a safety-driven study hold in late 2014. At trial resumption
      in early 2015, the remaining volunteers (n=51) received 3 x 10 E5 pfu. Thirteen volunteers
      received placebo. Among vaccinees, early immune responses were impressive, even at the lowest
      dose of 3 x 10 E5 pfu, and persisted well up to 6 months (last time point assessed). The
      trial successfully ended 12 months after injection. This prospective observational study will
      assess immune durability in this group of vaccinees at yearly time points up to five years
      post-vaccination.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>EBOV-specific IgG antibody titers measured by ELISA</measure>
    <time_frame>5 years after vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>EBOV-specific IgG antibody titers measured by ELISA</measure>
    <time_frame>2, 3, and 4 years after vaccination</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Immune Response</condition>
  <condition>Vaccination</condition>
  <condition>Durability</condition>
  <arm_group>
    <arm_group_label>vaccinated with 5 x 10E7 pfu VSV-ZEBOV</arm_group_label>
    <description>Volunteers vaccinated in 2014 or 2015 with 5 x 10E7 pfu VSV-ZEBOV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vaccinated with 10E7 pfu VSV-ZEBOV</arm_group_label>
    <description>Volunteers vaccinated in 2014 or 2015 with 10E7 pfu VSV-ZEBOV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vaccinated with 3 x 10E5 pfu VSV-ZEBOV</arm_group_label>
    <description>Volunteers vaccinated in 2014 or 2015 with 3 x 10E5 pfu VSV-ZEBOV</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood (RNA preservation)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Study participants are adults who were vaccinated according to the protocol of the Geneva
        phase I VSV-EBOV vaccine trial (NCT02287480) and who are willing and able to provide
        informed consent.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participated and was vaccinated with a single injection of VSV-EBOV at a dose of
             either 3 x 10E5 pfu, 10E7 pfu or 5 x 10E7 pfu in the Geneva phase I VSV-EBOV vaccine
             trial (NCT02287480).

          -  Able to provide written, informed consent for this observational study.

        Exclusion Criteria:

          -  Received additional vaccination with VSV-EBOV at similar or differing doses.

          -  Was lost to follow-up in the Geneva phase I VSV-EBOV vaccine trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>68 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claire-Anne Siegrist, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Geneva</affiliation>
  </overall_official>
  <reference>
    <citation>Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, Yerly S, Dayer JA, Kraehling V, Kasonta R, Adegnika AA, Altfeld M, Auderset F, Bache EB, Biedenkopf N, Borregaard S, Brosnahan JS, Burrow R, Combescure C, Desmeules J, Eickmann M, Fehling SK, Finckh A, Goncalves AR, Grobusch MP, Hooper J, Jambrecina A, Kabwende AL, Kaya G, Kimani D, Lell B, Lemaître B, Lohse AW, Massinga-Loembe M, Matthey A, Mordmüller B, Nolting A, Ogwang C, Ramharter M, Schmidt-Chanasit J, Schmiedel S, Silvera P, Stahl FR, Staines HM, Strecker T, Stubbe HC, Tsofa B, Zaki S, Fast P, Moorthy V, Kaiser L, Krishna S, Becker S, Kieny MP, Bejon P, Kremsner PG, Addo MM, Siegrist CA. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. N Engl J Med. 2016 Apr 28;374(17):1647-60. doi: 10.1056/NEJMoa1502924. Epub 2015 Apr 1.</citation>
    <PMID>25830326</PMID>
  </reference>
  <reference>
    <citation>Huttner A, Dayer JA, Yerly S, Combescure C, Auderset F, Desmeules J, Eickmann M, Finckh A, Goncalves AR, Hooper JW, Kaya G, Krähling V, Kwilas S, Lemaître B, Matthey A, Silvera P, Becker S, Fast PE, Moorthy V, Kieny MP, Kaiser L, Siegrist CA; VSV-Ebola Consortium. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis. 2015 Oct;15(10):1156-1166. doi: 10.1016/S1473-3099(15)00154-1. Epub 2015 Aug 4.</citation>
    <PMID>26248510</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2016</study_first_submitted>
  <study_first_submitted_qc>October 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2016</study_first_posted>
  <last_update_submitted>June 8, 2017</last_update_submitted>
  <last_update_submitted_qc>June 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Siegrist Claire-Anne</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

